Uterine cancer treatments market in need of drugs with high efficacy and safety profiles
The uterine cancer treatments market has been forecast to increase at a compound annual growth rate (CAGR) of 3.9% over the next five years, increasing from a total of $17.8 billion in 2013, to reach a total of $21.6 billion in 2018.
Growth in this market is being driven predominantly by research and development and a slight increase in the disease prevalence rate due to an aging population, diabetes, and obesity, according to a new report from BCC Research.
Uterine cancer is a common cancer of the female reproductive system that begins in the lining of the uterus. When cells in the lining of the uterus replicate themselves, genetic mutations can occur that result in aberrant cells. These cancerous cells multiply and form a tumor. These tumors can be invasive and metastasize into nearby tissues, often spreading throughout the body.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze